These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29886548)

  • 1. Biochemical Properties of Pathology-Related Tau Species in Tauopathy Brains: An Extraction Protocol for Tau Oligomers and Aggregates.
    Sahara N; Kimura T
    Methods Mol Biol; 2018; 1779():435-445. PubMed ID: 29886548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.
    Matsumoto G; Matsumoto K; Kimura T; Suhara T; Higuchi M; Sahara N; Mori N
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods for Biochemical Isolation of Insoluble Tau in Rodent Models of Tauopathies.
    Canet G; Rocaboy E; Diego-Diàz S; Whittington RA; Julien C; Planel E
    Methods Mol Biol; 2024; 2754():323-341. PubMed ID: 38512674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical isolation of insoluble tau in transgenic mouse models of tauopathies.
    Julien C; Bretteville A; Planel E
    Methods Mol Biol; 2012; 849():473-91. PubMed ID: 22528110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAPT mutations associated with familial tauopathies lead to formation of conformationally distinct oligomers that have cross-seeding ability.
    Bhopatkar AA; Bhatt N; Haque MA; Xavier R; Fung L; Jerez C; Kayed R
    Protein Sci; 2024 Sep; 33(9):e5099. PubMed ID: 39145409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and biophysical features of disease-associated tau mutants V363A and V363I.
    De Luigi A; Colombo L; Russo L; Ricci C; Bastone A; Cimini S; Tagliavini F; Rossi G; Cantù L; Del Favero E; Salmona M
    Biochim Biophys Acta Proteins Proteom; 2022 Mar; 1870(3):140755. PubMed ID: 34999006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformation determines the seeding potencies of native and recombinant Tau aggregates.
    Falcon B; Cavallini A; Angers R; Glover S; Murray TK; Barnham L; Jackson S; O'Neill MJ; Isaacs AM; Hutton ML; Szekeres PG; Goedert M; Bose S
    J Biol Chem; 2015 Jan; 290(2):1049-65. PubMed ID: 25406315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.
    Ward SM; Himmelstein DS; Ren Y; Fu Y; Yu XW; Roberts K; Binder LI; Sahara N
    Neurobiol Dis; 2014 Jul; 67():37-48. PubMed ID: 24631720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotoxicity of oligomers of phosphorylated Tau protein carrying tauopathy-associated mutation is inhibited by prion protein.
    Nieznanska H; Boyko S; Dec R; Redowicz MJ; Dzwolak W; Nieznanski K
    Biochim Biophys Acta Mol Basis Dis; 2021 Nov; 1867(11):166209. PubMed ID: 34246750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy.
    Eckermann K; Mocanu MM; Khlistunova I; Biernat J; Nissen A; Hofmann A; Schönig K; Bujard H; Haemisch A; Mandelkow E; Zhou L; Rune G; Mandelkow EM
    J Biol Chem; 2007 Oct; 282(43):31755-65. PubMed ID: 17716969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau Seeding Mouse Models with Patient Brain-Derived Aggregates.
    Robert A; Schöll M; Vogels T
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice.
    Guo JL; Narasimhan S; Changolkar L; He Z; Stieber A; Zhang B; Gathagan RJ; Iba M; McBride JD; Trojanowski JQ; Lee VM
    J Exp Med; 2016 Nov; 213(12):2635-2654. PubMed ID: 27810929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The twenty-four KDa C-terminal tau fragment increases with aging in tauopathy mice: implications of prion-like properties.
    Matsumoto SE; Motoi Y; Ishiguro K; Tabira T; Kametani F; Hasegawa M; Hattori N
    Hum Mol Genet; 2015 Nov; 24(22):6403-16. PubMed ID: 26374846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
    Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
    J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous tau aggregates in oligodendrocytes of rTg4510 mice induced by human P301L tau.
    Ren Y; Lin WL; Sanchez L; Ceballos C; Polydoro M; Spires-Jones TL; Hyman BT; Dickson DW; Sahara N
    J Alzheimers Dis; 2014; 38(3):589-600. PubMed ID: 24028867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of protein Tau by GSK3β prolongs survival of bigenic Tau.P301L×GSK3β mice by delaying brainstem tauopathy.
    Crespo-Biel N; Theunis C; Borghgraef P; Lechat B; Devijver H; Maurin H; Van Leuven F
    Neurobiol Dis; 2014 Jul; 67():119-32. PubMed ID: 24704314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Threonine
    Moszczynski AJ; Yang W; Hammond R; Ang LC; Strong MJ
    Acta Neuropathol Commun; 2017 Jan; 5(1):6. PubMed ID: 28077166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.
    Vega IE; Cui L; Propst JA; Hutton ML; Lee G; Yen SH
    Brain Res Mol Brain Res; 2005 Aug; 138(2):135-44. PubMed ID: 15913839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tauopathies and tau oligomers.
    Takashima A
    J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.